Ara
Toplam kayıt 5, listelenen: 1-5
Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores
(Elsevier, 2022)
Background & Aims: Currently available non-invasive tests, including fibrosis-4 index (FIB-4) and liver stiffness measurement (LSM by VCTE), are highly effective at excluding advanced fibrosis (AF) (F ≥3) or cirrhosis in ...
An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease
(AME Publishing Company, 2023)
Background: With the rising global prevalence of fatty liver disease related to metabolic dysfunction, the association of this common liver condition with chronic kidney disease (CKD) has become increasingly evident. In ...
Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study
(Lippincott Williams & Wilkins, 2023)
Background:Liver biopsy for the diagnosis of non-alcoholic steatohepatitis (NASH) is limited by its inherent invasiveness and possible sampling errors. Some studies have shown that cytokeratin-18 (CK-18) concentrations may ...
Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease
(Elsevier, 2023)
Background & Aims: Patients with fatty liver disease may experience stigma from the disease or comorbidities. In this crosssectional study, we aimed to understand stigma among patients with nonalcoholic fatty liver disease ...
Diagnostic accuracy of non-invasive tests to screen for at-risk MASH-An individual participant data meta-analysis
(Wiley, 2024)
Background & Aims: There is a need to reduce the screen failure rate (SFR) in metabolic dysfunction-associated steatohepatitis (MASH) clinical trials (MASH+F2-3; MASH+F4) and identify people with high-risk MASH (MASH+F2-4) ...